Cochrane · systematic review · CD013747
Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease
Okabayashi, S, Yamazaki, H, Yamamoto, R, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Certolizumab pegol compared to placebo for maintenance of remission in Crohn's disease
Population: people with Crohn's disease who responded to CZP remission‐induction treatment
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain clinical remission at week 26(1 RCT, 428 participants) Certolizumab pegol vs placebo | RR 0.73 [0.63, 0.85] | NR | Moderate Downgraded: imprecision |
Failure to maintain clinical response at week 26(1 RCT, 428 participants) Certolizumab pegol vs placebo | RR 0.58 [0.48, 0.71] | NR | Moderate Downgraded: imprecision |
Serious adverse events during remission maintenance treatment(1 RCT, 428 participants) Outcome: occurrence of infection, blood and lymphatic system disorder, immune system disorder, neoplasm, demyelinating disorders, drug‐induced systemic lupus er... Certolizumab pegol vs placebo | RR 0.84 [0.4, 1.78] | NR | Low Downgraded: imprecision |